<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-5362-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Durotine
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DULOXETINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        72.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Durotine Duloxetine HCL Capsules contains the active substance duloxetine. Duloxetine HCL Capsules increases the levels of serotonin and noradrenaline in the nervous system.Duloxetine HCL Capsules is used in adults to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generalized anxiety disorder (chronic feeling of anxiety or nervousness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetic neuropathic pain (often described as burning, stabbing, stinging, shooting or aching or like an electric shock. There may be loss of feeling in the affected area, or sensations such as touch, heat, cold or pressure may cause pain)</p><p>&nbsp;</p><p>Duloxetine HCL Capsules starts to work in most people with depression or anxiety within two weeks of starting</p><p>Treatment, but it may take 2-4 weeks before you feel better. Tell your doctor if you do not start&nbsp; to feel better after this time. Your doctor may continue to give you Duloxetine HCL Capsules when you are feeling better to prevent your depression or anxiety from returning</p><p>In people with diabetic neuropathic pain it can take some weeks before you feel better. Talk to your doctor if you do not feel better after 2 months.</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:398.25pt;height:208.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>DO NOT take </strong><strong>Duloxetine HCL Capsules if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to duloxetine or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe kidney disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking or have taken within the last 14 days, another medicine known as a monoamine oxidase inhibitor (MAOI) (see &lsquo;Taking other medicines&rsquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking fluvoxamine which is usually used to treat depression, ciprofloxacin or enoxacin which are used to treat some infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking other medicines containing duloxetine (see &lsquo;Taking other medicines&rsquo;)</p><p>Talk to your doctor if you have high blood pressure or heart disease. Your doctor will tell you if you should be taking Duloxetine HCL Capsules.</p><p>Warnings and precautions</p><p>The following are reasons why Duloxetine HCL Capsules may not be suitable for you. Talk to your doctor before you take Duloxetine HCL Capsules if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking other medicines to treat depression (see &lsquo;Taking other medicines&rsquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking St. John&rsquo;s Wort, a herbal treatment (Hypericum perforatum)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had seizures (fits)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had mania</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffer from bipolar disorder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have eye problems, such as certain kinds of glaucoma (increased pressure in the eye)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of bleeding disorders (tendency to develop bruises)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are at risk of low sodium levels (for example if you are taking diuretics, especially if you are elderly)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are currently being treated with another medicine which may cause liver damage</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking other medicines containing duloxetine (see &lsquo;Taking other medicines&rsquo;) Duloxetine HCL Capsules may cause a sensation of restlessness or an inability to sit or stand still. You should tell your doctor if this happens to you.</p><p>Thoughts of suicide and worsening of your depression or anxiety disorder</p><p>If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have previously had thoughts about killing or harming yourself</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are a young adult. Information from clinical trials has shown an increased risk of suicidal behavior in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant</p><p>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.</p><p>You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety Disorder, and ask them to read this leaflet.&nbsp; You&nbsp; might&nbsp; ask&nbsp; them&nbsp; to&nbsp; tell&nbsp; you&nbsp; if&nbsp; they think your depression or anxiety is getting worse, or if they are worried about changes in your behavior.</p><p>Children and adolescents under 18 years of age</p><p>Duloxetine HCL Capsules should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe Duloxetine HCL Capsules for patients under 18 because he/she decides that this is in their best interests. If your doctor has prescribed Duloxetine HCL Capsules for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if</p><p>any of the symptoms listed above develop or worsen when patients under 18 are taking Duloxetine HCL Capsules. Also the long-term safety effects concerning growth, maturation, and cognitive and behavioral development of Duloxetine HCL Capsules in this age group have not yet been demonstrated.</p><p>Other medicines and Duloxetine HCL Capsules</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>The main ingredient of Duloxetine HCL Capsules, duloxetine, is used in other medicines for other conditions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetic neuropathic pain, depression, anxiety and urinary incontinence</p><p>Using more than one of these medicines at the same time should be avoided. Check with your doctor if you are already taking other medicines containing duloxetine.</p><p>Your doctor should decide whether you can take Duloxetine HCL Capsules with other medicines. <strong>Do not start or stop taking any medicines, including those bought without a prescription and herbal remedies, before checking with your doctor.</strong></p><p>You should also tell your doctor if you are taking any of the following:</p><p><strong>Monoamine oxidase inhibitors (MAOIs): </strong>You should not take Duloxetine HCL Capsules if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI). Examples of MAOIs include moclobemide (an antidepressant) and linezolid (an antibiotic). Taking a MAOI together with many prescription medicines, including Duloxetine HCL Capsules, can cause serious or even life-threatening side effects. You must wait at least 14 days after you have stopped taking a MAOI before you can take Duloxetine HCL Capsules. Also, you need to wait at least 5 days after you stop taking Duloxetine HCL Capsules before you take a MAOI.</p><p><strong>Medicines that cause sleepiness: </strong>These include medicines prescribed by your doctor including benzodiazepines, strong painkillers, antipsychotics, phenobarbital and antihistamines.</p><p><strong>Medicines that increase the level of serotonin: </strong>Triptans, tramadol, tryptophan, SSRIs (such as paroxetine and fluoxetine), SNRIs (such as venlafaxine), tricyclic antidepressants (such as</p><p>clomipramine, amitriptyline), pethidine, St John&rsquo;s Wort and MAOIs (such as moclobemide and linezolid). These medicines increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with Duloxetine HCL Capsules, you should see your doctor.</p><p><strong>Oral anticoagulants or antiplatelet agents: </strong>Medicines which thin the blood or prevent the blood from clotting. These medicines might increase the risk of bleeding.</p><p>Duloxetine HCL Capsules with food, drink and alcohol</p><p>Duloxetine HCL Capsules may be taken with or without food. Care should be taken if you drink alcohol while you are being treated with Duloxetine HCL Capsules</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you become pregnant, or you are trying to become&nbsp; pregnant, while you are taking Duloxetine HCL Capsules. You should use Duloxetine HCL Capsules only after discussing the potential benefits and any potential risks to your unborn child with your doctor.</p><p>Make sure your midwife and/or doctor knows you are on Duloxetine HCL Capsules. When taken during</p><p>Pregnancy, similar drugs (SSRIs) may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.</p><p>If you take Duloxetine HCL Capsules near the end of your pregnancy, your baby might have some symptoms when it is born. These usually begin at birth or within a few days of your baby being born. These symptoms may include floppy muscles, trembling, jitteriness, not feeding properly, trouble with breathing and fits. If your baby has any of these symptoms when it is born, or you are concerned about your baby&rsquo;s health, contact your doctor or midwife who will be able to advise you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you are breast-feeding. The use of Duloxetine HCL Capsules while breastfeeding is not recommended. You should ask your doctor or pharmacist for advice.</p><p>Driving and using machines</p><p>Duloxetine HCL Capsules may make you feel sleepy or dizzy. Do not drive or use any tools or machines until you know how Duloxetine HCL Capsules affects you.</p><p>Duloxetine HCL Capsules contains sucrose</p><p>Duloxetine HCL Capsules contains sucrose. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Duloxetine HCL Capsules is for oral use. You should swallow your capsule whole with a drink of water.</p><p>For depression and diabetic neuropathic pain:</p><p>The usual dose of Duloxetine HCL Capsules is 60 mg once a day, but your doctor will prescribe the dose that is right for you.</p><p>For generalized anxiety disorder:</p><p>The usual starting dose of Duloxetine HCL Capsules is 30 mg once a day after which most patients will receive 60 mg once a day, but your doctor will prescribe the dose that is right for you. The dose may be adjusted up to 120 mg a day based on your response to Duloxetine HCL Capsules.</p><p>To help you remember to take Duloxetine HCL Capsules, you may find it easier to take it at the same times every day.</p><p>Talk with your doctor about how long you should keep taking Duloxetine HCL Capsules. Do not stop taking Duloxetine HCL Capsules, or change your dose, without talking to your doctor.</p><p>Treating your disorder properly is important to help you get better. If it is not treated, your condition may not go away and may become more serious and difficult to treat.</p><p>If you take more Duloxetine HCL Capsules than you should</p><p>Call your doctor or pharmacist immediately if you take more than the amount of Duloxetine&nbsp; HCL Capsules prescribed by your doctor. Symptoms of overdose include sleepiness, coma, serotonin syndrome (a rare reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles), fits, vomiting and fast heart rate.</p><p>If you forget to take Duloxetine HCL Capsules</p><p>If you miss a dose, take it as soon as you remember. However, if it is time for your next dose, skip the missed dose and take only a single dose as usual. Do not take a double dose to make up for a forgotten dose. Do not take more than the daily amount of Duloxetine HCL Capsules that has been prescribed for you in one day.</p><p>If you stop taking Duloxetine HCL Capsules</p><p>DO NOT stop taking your capsules without the advice of your doctor even if you feel better. If your doctor thinks that you no longer need Duloxetine HCL Capsules he or she will ask you to reduce your dose over at least 2 weeks before stopping treatment altogether.</p><p>Some patients who stop taking Duloxetine HCL Capsules suddenly have had symptoms such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, tingling feelings like pins and needles or electric shock-like feelings (particularly in the head), sleep disturbances (vivid dreams, nightmares, inability to sleep), fatigue, sleepiness, feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), shaking (tremor), headaches, muscle pain, feeling irritable, diarrhoea, excessive sweating or vertigo.</p><p>These symptoms are usually not serious and disappear within a few days, but if you have symptoms that are troublesome you should ask your doctor for advice.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. These effects are normally mild to moderate and often disappear after a few weeks.</p><p>Very common side effects (may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, feeling sleepy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), dry mouth</p><p>Common side effects (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping, feeling agitated, less sex drive, anxiety, difficulty or failure to experience orgasm, unusual dreams</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, feeling sluggish, tremor, numbness, including numbness, pricking or tingling of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred eyesight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tinnitus (hearing sound in the ear when there is no external sound)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling the heart pumping in the chest,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure, flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased yawning</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, diarrhoea, stomach pain, being sick (vomiting), heartburn or indigestion, breaking wind</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating, (itchy) rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain, muscle spasm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful urination, frequent urination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems getting an erection, changes in ejaculation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; falls (mostly in elderly people), fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>Children and adolescents under 18 years of age with depression treated with this medicine had some weight loss when they first start taking this medicine. Weight increased to match other children and adolescents of their age and sex after 6 months of treatment.</p><p>Uncommon side effects (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; throat inflammation that causes a hoarse voice</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicidal thoughts, difficulty sleeping, grinding or clenching the teeth, feeling disorientated, lack of motivation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden involuntary jerks or twitches of the muscles, sensation of restlessness or an inability to sit or stand still, feeling nervous, difficulty concentrating, changes in sense of taste, difficulty controlling movement e.g. lack of coordination or involuntary movements of the muscles, restless legs syndrome, poor sleep quality</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; large pupils (the dark centre of the eye), problems with eyesight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of dizziness or &ldquo;spinning&rdquo; (vertigo), ear pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast and/or irregular heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting, dizziness, lightheadedness or fainting on standing up, cold fingers and/or toes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; throat tightness, nose bleeds</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting blood, or black tarry stools (faeces), gastroenteritis, burping, difficulty swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver that may cause abdominal pain and yellowing of the skin or whites of the eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; night sweats, hives, cold sweats, sensitivity to sunlight, increased tendency to bruise</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle tightness, muscle twitching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty or inability to pass urine, difficulty to start urinating, needing to pass urine during the night, needing to pass more urine than normal, having a decreased urine flow</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal vaginal bleeding, abnormal periods, including heavy, painful, irregular or prolonged periods, unusually light or missed periods, pain in the testicles or scrotum</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain, feeling cold, thirst, shivering, feeling hot, abnormal gait</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Duloxetine HCL Capsules may cause effects that you may not be aware of, such as increases in liver enzymes or blood levels of potassium, creatine phosphokinase, sugar, or cholesterol</p><p>Rare side effects (may affect up to 1 in 1000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reaction which causes difficulty in breathing or dizziness with swollen tongue or lips, allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased thyroid gland activity which can cause tiredness or weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration, low levels of sodium in the blood (mostly in elderly people; the symptoms may include feeling dizzy, weak, confused, sleepy or very tired, or feeling or being sick, more serious symptoms are fainting, fits or falls), syndrome of inappropriate secretion of anti-diuretic hormone (SIADH)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicidal behaviour, mania (over activity, racing thoughts and decreased need for sleep), Hallucinations, aggression and anger</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ldquo;Serotonin syndrome&rdquo; (a rare reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles),fits</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased pressure in the eye (glaucoma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the mouth, passing bright red blood in your stools, bad breath inflammation of the large intestine (leading to diarrhoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure, yellowing of the skin or whites of the eyes (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome (serious illness with blistering of the skin, mouth, eyes and genitals), serious allergic reaction which causes swelling of the face or throat (angioedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; contraction of the jaw muscle</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal urine odour</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Menopausal symptoms, abnormal production of breast milk in men or women.</p><p>Very rare side effects (may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the blood vessels in the skin (cutaneous vasculitis)</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information.</p><p><strong><em>&nbsp;&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>o Other GCC States:</em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package to protect from moisture. Do not store above 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>The active substance is duloxetine hydrochloride delayed release capsules 30mg:</u></strong></p><p>Each Delayed Release Capsule Contains Duloxetine Hydrochloride Equivalent to Duloxetine 30mg</p><p><strong><u>The active substance is duloxetine hydrochloride delayed release capsules 60mg</u></strong>:</p><p>Each Delayed Release Capsule Contains Duloxetine Hydrochloride Equivalent to Duloxetine 60mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Capsule content: Sugar spheres (Pharmaspheres 710-850&micro;), Hypromellose (Methocel E5 LV), Crospovidone (Kollidon CL M), Talc (Talc Luzenac Pharma), Sucrose (P.G Sugar #40 #80), Carboxy methyl ethyl cellulose (CMEC), Povidone (Plasdone K29/32), Isopropyl alcohol.</p><p>Film&nbsp;&nbsp;&nbsp;&nbsp; coating&nbsp;&nbsp;&nbsp;&nbsp; composition:&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose, Titanium Dioxide, Polyethylene glycol, polysorbate 80, Talc, Purified Water.</p><p>Empty hard gelatin capsule shells, size &quot;3&quot;, Cap color -Opaque blue and Body color - Opaque white imprinted with &#39;H&#39; on cap and &#39;191&#39; on body with golden yellow color ink. Empty hard gelatin capsule shells, size &quot;1&quot;, Cap color -Opaque blue and Body color - Opaque white imprinted with &#39;H&#39; on cap and &#39;192&#39; on body with golden yellow color ink.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Duloxetine HCL Capsules looks like?

Duloxetine Hydrochloride Delayed Release Capsules 30 mg

Opaque blue cap / Opaque white body size ‘3’ hard gelatin capsule imprinted with ‘H’ on cap and ‘191’ on body, with golden yellow ink, filled with white to off white colored pellets.

Duloxetine Hydrochloride Delayed Release Capsules 60 mg

Opaque blue cap / Opaque green body size ‘1’ hard gelatin capsule imprinted with ‘H’ on cap and ‘192’ on body, with white ink, filled with white to off white colored pellets.

How supplied:

Duloxetine HCL Capsules are supplied in Blister pack.

Duloxetine HCL Capsules 30mg

4 X 7`s Alu-Alu Blisters Pack.

Duloxetine HCL Capsules 60mg

3 X 10`s Alu-Alu Blisters Pack.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 2215</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                February, 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ديوروتين كبسولات على دولوكسيتين هيدروكلوريد . ديوروتين كبسولات تزيد من مستويات السيروتونين أندروأدرينالين في الجهاز العصبي .</p><p dir="RTL">وتستخدم ديوروتين كبسولات كبسولات للبالغين في علاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإكتئاب .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات القلق العام (الشعور المزمن بالقلق أو العصبية) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألام اعتلال الأعصاب السكري (غالبا ما يوصف على شكل الشعور بحرقان أو وخذ أو لذخ مؤلم أو ما يشبه صدمة كهربائية قد يكون هناك فقدان للشعور في المنطقة المصابة ، أو قد يسبب الإحساس بالحرارة أو البرد أو ضغط يسبب الألم) .</p><p dir="RTL">تظهر فعالية ديوروتين كبسولات في معظم الناس الذين يعانون من الاكتئاب أو القلق في غضون أسبوعين من بدء العلاج ، ولكن قد يستغرق 2-4 أسابيع قبل أن تشعر بالتحسن . أخبر طبيبك إذا كنت لا تبدأ في الشعور بالتحسن بعد هذا الوقت . قد يستمر طبيبك في إعطائك ديوروتين كبسولات لمنع عودة الشعور بالاكتئاب أو القلق .</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأشخاص الذين يعانون من آلام الاعتلال العصبي السكري قد يستغرق الأمر بضعة أسابيع قبل أن تشعر بالتحسن . تحدث إلى طبيبك إذا لم تشعر بتحسن بعد شهرين .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال ديوروتين كبسولات:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه دولوكسيتين هيدروكلوريد أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض الكبد .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض شديدة بالكلى .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت خلال ال 14 يوما الماضية ، دواء آخر يعرف باسم مثبطات&nbsp;أكسيداز أحادي الأمين (MAOI) (انظر &quot;تناول أدوية أخرى&quot;) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول فلوفوكسامين الذي يستخدم لعلاج الاكتئاب ، سيبروفلوكساسين أو إينوكساسينوهيتش تستخدم لعلاج بعض الالتهابات .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تناول أدوية أخرى تحتوي على دولوكسيتين (انظر &quot;تناول أدوية أخرى&quot;)</p><p dir="RTL">تحدث إلى طبيبك إذا كنت تعاني من ارتفاع في ضغط الدم أو أمراض بالقلب . سوف يخبرك طبيبك إذا كان يجب عليك أن تتناول ديوروتين كبسولات .</p><p dir="RTL"><strong>التحذيرات والاحتياطات:</strong></p><p dir="RTL">فيما يلى الاسباب التى تجعل تناول ديوروتين كبسولات غير مناسب لك . تحدث مع طبيبك قبل تناول ديوروتين كبسولات إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تتناول أدوية أخرى لعلاج الاكتئاب (انظر &quot;تناول أدوية أخرى&quot;) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تتناول نبتة سانت جون ، والعلاج بالأعشاب الأخرى (العرن المثقوب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تعانى من أمراض بالكلى .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت أصبت مسبقا بتشنجات (نوبات) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تعانى من الهوس .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تعانى من الاضطراب الوجداني ثنائي القطب&nbsp;.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كان لديك مشاكل في العين ، مثل بعض أنواع الجلوكوما (زيادة ضغط العين) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت عانيت مسبقا من اضطرابات النزيف (ظهور الكدمات بشكل زائد) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت في خطرمن انخفاض مستويات الصوديوم (على سبيل المثال إذا كنت تتناول مدرات البول ، وخاصة إذا كنت مسن) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تتناول حاليا دواء قد يتسبب في تلف الكبد .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تتناول أدوية أخرى تحتوي على دولوكسيتين (انظر &quot;تناول أدوية أخرى&quot;) .</p><p dir="RTL"><strong>الأفكار الانتحارية وتفاقم الاكتئاب أو نوبات القلق</strong></p><p dir="RTL">إذا كنت تعاني من الاكتئاب أو لديك نوبات القلق أو يمكن أن يكون لديك أحيانا أفكار من الإضرار أو قتل نفسك . ويمكن زيادة هذه الأعراض عند بدء تناول مضادات الاكتئاب الأولى ، لأن هذه الأدوية كلها تستغرق وقتا طويلا للعمل ، وعادة حوالي أسبوعين ولكن في بعض الأحيان تستغرق وقت أطول .</p><p dir="RTL">قد تكون أكثر عرضة للتفكير في مثل هذا إذا كنت:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كانت لديك أفكار حول الانتحار .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت شابا . فقد أظهرت معلومات من التجارب السريرية زيادة خطر الانتحار في البالغين الذين تقل أعمارهم عن 25 عاما مع الحالات النفسية والذين عولجوا بتناول مضادات الإكتئاب .</p><p dir="RTL"><strong>إذا كان لديك أفكار عن إلحاق الضرر بنفسك أو قتل نفسك في أي وقت ، اتصل بطبيبك أو انتقل إلى المستشفى على الفور .</strong></p><p dir="RTL">قد تجد أنه من المفيد أن تخبر قريب أو صديق مقرب أنك مكتئب أو لديك اضطرابات قلق ، واطلب منهم قراءة هذه النشرة . قد تطلب منهم أن يخبروك إذا كانوا يعتقدون أن حالة الاكتئاب أو القلق تزداد سوءا ، أو إذا كانوا قلقين بشأن تغييرات في سلوكك .</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">يجب عدم استخدام ديوروتين كبسولات للأطفال والمراهقين الذين تقل أعمارهم عن 18 عاما . أيضا ، يجب معرفة أن المرضى تحت سن 18 عام واللذين يتناولون ديوروتين كبسولات لديهم خطر متزايد من حدوث آثار جانبية مثل محاولة الانتحار ، والأفكار الانتحارية والعدائية (في الغالب السلوك العدواني ، المعارض والغضب) . على الرغم من ذلك ، قد يصف طبيبك ديوروتين كبسولات للمرضى دون سن 18 عاما لأنه يقرر أن هذا في مصلحتهم . إذا كان طبيبك قد وصف ديوروتين كبسولات لمريض دون سن 18 وكنت ترغب في مناقشة ذلك ، يرجى العودة إلى الطبيب . ويجب عليك إبلاغ الطبيب إذا كان أي من الأعراض المذكورة أعلاه تتطور أو تزداد سوءا عند المرضى الذين تقل أعمارهم عن 18 عام ويتناولون ديوروتين كبسولات . أيضا ينبغي العلم أن التأثير الآمن لتناول ديوروتين كبسولات على المدى الطويل والمتعلقة بالنمو ، والنضج ، والتنمية المعرفية والسلوكية لهذه الفئة العمرية لم تحدد بعد .</p><p dir="RTL"><strong>تناول أدوية أخرى مع </strong><strong>ديوروتين كبسولات</strong><strong>: </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت تناولت ، أو قد تتناول مؤخرا أي أدوية أخرى بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية .</p><p dir="RTL">المادة الفعالة الموجودة ديوروتين كبسولات (دولوكسيتين) تستخدم في أدوية أخرى لحالات أخرى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألام الأعصاب السكري ، والاكتئاب ، والقلق وسلس البول</p><p dir="RTL">ينبغي تجنب استخدام أكثر من واحد من هذه الأدوية في نفس الوقت . تحقق مع طبيبك إذا كنت تتناول بالفعل أدوية أخرى تحتوي على دولوكسيتين .</p><p dir="RTL">يجب أن يقرر طبيبك ما إذا كان بإمكانك تناول ديوروتين كبسولات مع أدوية أخرى . لا تبدأ أو تتوقف عن تناول أي دواء ، بما في ذلك تلك التي تم شراؤها بدون وصفة طبية والعلاجات العشبية ، قبل التحقق مع طبيبك .</p><p dir="RTL">يجب عليك أيضا إخبار طبيبك إذا كنت تتناول أي مما يلي:</p><p dir="RTL">مثبطات&nbsp;أكسيداز أحادي الأمين (MAOI): يجب عدم تناول ديوروتين كبسولات إذا كنت تتناول ، أو قد تناولت مؤخرا (في غضون الأيام ال 14 الماضية) مضاد للاكتئاب يسمى مثبطات&nbsp;أكسيداز أحادي الأمين (MAOI) . وتشمل الأمثلة على MAOI موكلوبيميد (مضاد للاكتئاب) و لينزوليد (مضاد حيوي) . تناول MAOI جنبا إلى جنب مع العديد من الأدوية ، بما في ذلك ديوروتين كبسولات ، يمكن أن يسبب آثار جانبية خطيرة وقد تكون مهددة للحياة . يجب عليك الانتظار لمدة 14 يوما على الأقل بعد التوقف عن تناول MAOI قبل أن تبدء في تناول ديوروتين كبسولات . أيضا ، تحتاج إلى الانتظار 5 أيام على الأقل بعد التوقف عن تناول ديوروتين كبسولات قبل تناول مثبطات&nbsp;أكسيداز أحادي الأمين .</p><p dir="RTL">الأدوية التي تسبب النعاس الموصوفة من قبل الطبيب: بما في ذلك</p><p dir="RTL">البنزوديازيبينات ، المسكنات القوية ، مضادات الذهان ، الفينوباربيتال ومضادات الهيستامين .</p><p dir="RTL">الأدوية التي تزيد من مستوى السيروتونين: تريبتان ، ترامادول ، تريبتوفان ، مثبطات استرداد&nbsp;السيروتونين&nbsp;الاختيارية (مثل باروكسيتين و فلوكستين) ، مثبطات استرداد&nbsp;السيروتونين&nbsp;الاختيارية (مثل فينلافاكسين) ، مضادات الاكتئاب ثلاثية الحلقات (مثل كلوميبرامين ، أميتريبتيلين) ، البيثيدين ، نبتة سانت جون و مثبطات&nbsp;أكسيداز أحادي الأمين (مثل موكلوبميد و لينيزوليد) . هذه الأدوية تزيد من خطر الآثار الجانبية . إذا كنت تعاني من أي أعراض غير عادية أثناء تناول أي من هذه الأدوية جنبا إلى جنب مع ديوروتين كبسولات ، يجب زيارة الطبيب .</p><p dir="RTL">المضادات التخثرية عن طريق الفم أو العوامل المضادة للصفيحات: الأدوية التي تعمل على سيولة الدم أو تمنع الدم من التخثر . هذه الأدوية قد تزيد من خطر النزيف .</p><p dir="RTL"><strong>تناول ديوروتين كبسولات</strong><strong> </strong><strong>مع الطعام والشراب والكحول</strong></p><p dir="RTL">يمكن تناول ديوروتين كبسولات مع أو بدون الطعام . يجب توخي الحذر إذا كنت تشرب الكحول أثناء العلاج بتناول ديوروتين كبسولات .</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية:</strong></p><p dir="RTL">إذا كنت حاملا أو مرضعة ، تعتقد أنك قد تكون حاملا أو تخطط للرضاعة الطبيعية ، اطلب من طبيبك أو الصيدلي تقديم المشورة قبل تناول هذا الدواء .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت حاملا ، أو إذا كنت تخططي للحمل ، أثناء تناول ديوروتين كبسولات . يجب عليك استخدام ديوروتين كبسولات فقط بعد مناقشة الفوائد المحتملة والمخاطر المحتملة لطفلك الذي لم يولد بعد مع طبيبك .</p><p dir="RTL">تأكد من أن المولدة أو الطبيب على علم أنك تتناول ديوروتين كبسولات .</p><p dir="RTL">عند تناول ديوروتين كبسولات خلال</p><p dir="RTL">الحمل ، والأدوية المماثلة (مثبطات استرداد&nbsp;السيروتونين&nbsp;الاختيارية) قد يزيد من خطر حدوث حالة خطيرة في الأطفال ، وارتفاع ضغط الدم الرئوي المستمر لحديثي الولادة ، مما يجعل الطفل يتنفس أسرع ويبدو عليه اللون الأزرق . وعادة ما تبدأ هذه الأعراض خلال ال 24 ساعة الأولى بعد ولادة الطفل . إذا حدث ذلك لطفلك ، يجب عليك الإتصال بالمولدة و / أو الطبيب فورا .</p><p dir="RTL">إذا تناولت ديوروتين كبسولات بالقرب من نهاية حملك ، قد يكون لدى طفلك بعض الأعراض عند ولادته . هذه الأعراض عادة ما تبدأ عند الولادة أو في غضون بضعة أيام من ولادة طفلك . وقد تشمل هذه الأعراض تسطح&nbsp;العضلات ، الإرتجاف ، والارتعاش ، وعدم التغذية بشكل صحيح ، ومشاكل في التنفس ونوبات . إذا كان طفلك يعاني من أي من هذه الأعراض عند ولادته ، أو إذا كنت مهتما بصحة طفلك ، اتصل بطبيبك أو المولدة التي ستتمكن من إرشادك .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت في مرحلة الرضاعة الطبيعية . لا ينصح بتناول ديوروتين كبسولات أثناء الرضاعة الطبيعية . يجب عليك أن تطلب من الطبيب أو الصيدلي الحصول على المشورة .</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تجعلك ديوروتين كبسولات تشعر بالنعاس أو بالدوار . لا تقود أو تستخدم أي أدوات أو آلات حتى تعرف كيف تؤثر ديوروتين كبسولات عليك .</p><p dir="RTL"><strong>محتوى ديوروتين كبسولات من السكريات .</strong></p><p dir="RTL">تحتوي ديوروتين كبسولات على السكروز . إذا أخبرك طبيبك من قبل أن لديك مشكلة تجاه تناول بعض السكريات ، اتصل بطبيبك قبل تناول ديوروتين كبسولات .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدواء كما وصف لك الطبيب ، استشر الطبيب أو الصيدلي إن لم تكن متأكداً .</p><p dir="RTL">يتم تناول ديوروتين كبسولات عن طريق الفم . يجب ابتلاع الكبسولة بأكملها مع شراب من الماء .</p><p dir="RTL"><strong>للاكتئاب وآلام الاعتلال العصبي السكري:</strong></p><p dir="RTL">الجرعة المعتادة من ديوروتين كبسولات هي 60 ملغم مرة واحدة في اليوم ، ولكن سوف يصف طبيبك الجرعة المناسبة لك .</p><p dir="RTL"><strong>للاضطراب القلق العام:</strong></p><p dir="RTL">جرعة البداية المعتادة من ديوروتين كبسولات 30 ملغم مرة واحدة في اليوم بعد ذلك سوف يتناول معظم المرضى 60 ملغم مرة واحدة في اليوم ، و سوف يصف طبيبك الجرعة المناسبة . يمكن تعديل الجرعة لتصل إلى 120 ملغم يوميا بناء على استجابتك لديوروتين كبسولات.</p><p dir="RTL">لمساعدتك على تذكر أن تتناول ديوروتين كبسولات ، قد تجد أنه من الأسهل أن تتناول الجرعة في نفس الأوقات من كل يوم .</p><p dir="RTL">تحدث مع طبيبك حول المدة التي يجب أن تتناول ديوروتين كبسولات فيها . لا تتوقف عن تناول ديوروتين كبسولات ، أو تغيير الجرعة ، دون التحدث إلى طبيبك . من المهم استخدام العلاج المناسب لك بشكل صحيح لمساعدتك على التحسن . إذا لم يتم العلاج ، قد لا تختفي الأعراض وقد تصبح أكثر خطورة ويصعب علاجها .</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من ديوروتين كبسولات:</strong></p><p dir="RTL">يجب الاتصال بطبيبك أو الصيدلي إذا تتناولت ديوروتين كبسولات أكثر من الجرعة اليومية التي تم وصفها لك في يوم واحد . أعراض الجرعة الزائدة تشمل النعاس ، والغيبوبة ، ومتلازمة السيروتونين (رد فعل نادر قد يسبب مشاعر السعادة العظيمة ، والنعاس ، الحماقات ، والأرق ، والشعور أنك في حالة سكر ، والحمى ، والتعرق أو تصلب العضلات) ، نوبات ، والتقيؤ وسرعة ضربات القلب .</p><p dir="RTL"><strong>إذا نسيت تناول ديوروتين كبسولات:</strong></p><p dir="RTL">إذا نسيت تناول جرعة تناولها حينما تتذكرها . ومع ذلك ، إذا اقترب وقت الجرعة التالية ، تخطي الجرعة المنسية وتناول الجرعة الاعتيادية كالمعتاد . لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية . لا تتناول ديوروتين كبسولات أكثر من الجرعة اليومية التي تم وصفها لك في يوم واحد.</p><p dir="RTL"><strong>التوقفت عن تناول ديوروتين كبسولات:</strong></p><p dir="RTL">لا تتوقف عن تناول كبسولاتك دون أن ينصحك الطبيب بذلك حتى لو كنت تشعر بتحسن . إذا كان طبيبك يعتقد أنك لم تعد بحاجة إلى تتناول ديوروتين كبسولات إنه أو أنها سوف يطلب منك تقليل الجرعة التي تتناولها على الأقل لمدة اسبوعين قبل التوقف عن العلاج تماما .</p><p dir="RTL">بعض المرضى الذين يتوقفون عن تتناول ديوروتين كبسولات قد يواجهون أعراض مفاجئة مثل:</p><p dir="RTL">دوخة والشعور بوخز مثل الدبابيس والإبر أو المشاعر الشبيهة بالكهرباء (خاصة في الرأس) ، واضطرابات النوم (أحلام حية ، والكوابيس ، وعدم القدرة على النوم) ، والتعب ، والنعاس ، والشعور بعدم الارتياح أو التحريك ، والشعور بالقلق ، والشعور بالمرض (الغثيان) أو المرضى (القيء) ، والهز (الرعشة) ، والصداع ، وآلام في العضلات ، والشعور بالعرق ، والإسهال ، والتعرق الزائد أو الدوار .</p><p dir="RTL">وعادة ما تكون هذه الأعراض غير خطيرة وتختفي في غضون أيام قليلة ، ولكن إذا كان لديك أعراض مزعجة يجب عليك أن تطلب من الطبيب المشورة .</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يتسبب هذا الدواء &nbsp;في آثار جانبية ، على الرغم من أنها لا تؤثر في الجميع . إذ أنها تكون عادة طفيفة وتختفي بعد بضعة أسابيع .</p><p dir="RTL"><strong>أعراض جانبية شائعة جدا (قد تصيب أكثر من شخص من أصل 10 أشخاص) .</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع ، والشعور بالنعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالمرض (الغثيان) وجفاف الفم</p><p dir="RTL"><strong>أعراض جانبية شائعة (قد تصيب أقل من شخص من أصل 10 أشخاص) .</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في النوم ، والشعور بالضيق ، وانخفاض الدافع الجنسي ، والقلق ، صعوبة أو فشل في الحصول على النشوة الجنسية ، أحلام غير عادية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة ، والشعور بالكسل ، ورعشة ، وخذ ، بما في ذلك التنميل ، وخز بالجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين بالأذن (سماع صوت في الأذن على الرغم من عدم وجود صوت خارجي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بنبض القلب في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ضغط الدم ، تدفق الدم في الوجه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التثاؤب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك ، والإسهال ، وآلام في المعدة ، والإعياء (القيء) ، حرقة أو عسر الهضم ، الغائط المفرط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق ، (حكة) الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في العضلات ، تشنج العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التبول المؤلم ، وكثرة التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الحصول على الانتصاب ، والتغيرات في القذف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السقوط على الأرض (معظمهم من المسنين) ، والتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">الأطفال والمراهقين الذين تقل أعمارهم عن 18 عاما الذين يعانون من الاكتئاب ويتناولون هذا الدواء معرضين لفقدان الوزن عند البدء في تناول هذا الدواء . وسيعود الوزن لطبيعته مقارنة بالأطفال والمراهقين الآخرين من سنهم وجنسهم بعد 6 أشهر من العلاج .</p><p dir="RTL"><strong>أعراض جانبية غير شائعة (قد تصيب ما يصل إلى شخص من أصل 100 شخص) .</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق الذي يسبب صوت أجش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار انتحارية ، وصعوبة في النوم ، وطحن أو تقطيع الأسنان ، والشعور بالارتباك ، وعدم وجود حافز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهزات الغير إرادية المفاجئة أو نوبات بالعضلات أو الإحساس بالألم أو عدم القدرة على الجلوس أو الوقوف ، والشعور بالتوتر ، وصعوبة التركيز ، والتغيرات في التزوق ، وصعوبة التحكم في الحركة ، على سبيل المثال . عدم وجود تنسيق أو حركات غير إرادية للعضلات ، متلازمة تململ&nbsp;الساقين ، وعدم الراحة في النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتساع حدقة العين (الدائرة القاتمة في العين) ، ومشاكل في البصر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار أو (الدوار) ، ألم الأذن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب السريعة و / أو غير المنتظمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء ، والدوخة ، والدوار أو الإغماء أثناء الوقوف ، والأصابع الباردة باليدين و / أو أصابع القدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الحلق ، نزيف بالأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقيؤ دموي ، أو &nbsp;البراز الأسود&nbsp;القطراني ، التهاب المعدة والأمعاء ، التجشؤ ، صعوبة في البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد الذي قد يسبب ألم في البطن وأصفرار الجلد أو بياض العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق ليلي ، وأرتيكاريا ، والتعرق البارد ، والحساسية لأشعة الشمس ، وزيادة الميل إلى تكوين كدمات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب العضلات ، ورعشة بالعضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة أو عدم القدرة على تمرير البول ، وصعوبة لبدء التبول ، والحاجة إلى تمرير البول ليلا ، وتحتاج إلى تمرير البول أكثر من المعتاد ، وجود انخفاض تدفق البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف مهبلي غير طبيعي ، عدم انتظام الدورة الشهرية ، بما في ذلك الدورة الشهرية الثقيلة والمؤلمة ، غير المنتظمة أو لفترات طويلة ، على غير عادي أن تكون خفيفة أو فترات تغيب ، ألم في الخصيتين أو كيس الصفن .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر ، والشعور بالبرد ، والعطش ، الإرتجاف ، والشعور بالحرارة ، مشية غير طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تسبب ديوروتين كبسولات تأثيرات قد لا تكون على دراية بها ، مثل الزيادات في إنزيمات الكبد مستويات البوتاسيوم في الدم ، فوسفوكيناز الكرياتين ، والسكر ، أو الكولسترول</p><p dir="RTL"><strong>أعراض جانبية نادرة (قد تصيب ما يصل إلى شخص من أصل 100 شخص) .</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي خطير والذي يسبب صعوبة في التنفس أو الدوخة مع تورم اللسان أو الشفاة ، الحساسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نشاط الغدة الدرقية والذي يمكن أن يسبب التعب أو زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف وانخفاض مستويات الصوديوم في الدم ( معظمها في المسنين ؛ قد تشمل الأعراض على الشعور بالدوار أو الضعف أو الإختلاط أو النعاس أو التعب الشديد أو الشعور أو الإعياء ، والأعراض الشديدة هي الإغماء أو السقوط) متلازمة&nbsp;الإفراز غير الملائم للهرمون المضاد لإدرار البول .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السلوك الانتحاري ، والهوس (زيادة النشاط ، تسابق الأفكار وانخفاض الحاجة إلى النوم) ، الهلوسة والعدوانية والغضب .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;متلازمة السيروتونين&quot; (حالة نادرة &nbsp;قد تسبب مشاعر السعادة العظيمة ، والنعاس ، الحماقات ، والأرق ، والشعور بأنك في حالة سكر ، والحمى ، والتعرق أو تصلب العضلات) ، نوبات .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;زيادة ضغط العين (جلوكوما) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم ، ظهور الدم الأحمر في البراز ، رائحة الفم الكريهة من الأمعاء الغليظة (مما تؤدي إلى الإسهال) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل بالكبد ، اصفرار الجلد أو بياض العينين (اليرقان) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز جونسون (مرض خطير يصيب الجلد والفم والعيون والأعضاء التناسلية) ، ورد فعل تحسسي خطير يسبب تورم في الوجه أو الحلق (الوذمة الوعائية) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلص عضلة الفك .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رائحة البول غير طبيعية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض انقطاع الطمث ، إفراز غير طبيعي من حليب الثدي في الرجال أو النساء .</p><p dir="RTL"><strong>أعراض جانبية نادرة جدا (قد تصيب ما يصل إلى شخص من أصل 10000 شخص) .</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية في الجلد (التهاب الأوعية الدموية الجلدية) .</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة&nbsp; أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي . وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة . يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه) . بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء .</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم ديوروتين كبسولات بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية . تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم حفظ العبوة في درجة حرارة أعلى من 30 درجة مئوية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يتم حفظ العبوة بعيدا عن الرطوبة .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية . اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة . هذه التدابير تساعد في الحفاظ على البيئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;ما تحويه علبة ديوروتين كبسولات: </strong></p><p dir="RTL">المادة الفعالة هي دولوكسيتين هيدروكلوريد.</p><p dir="RTL">تحتوي كل كبسولة على 30 أو 60 ملغم من دولوكسيتين (على هيئة هيدروكلوريد) .</p><p dir="RTL">الصواغات الأخرى هي:</p><p dir="RTL">محتوى كبسولة: كرات السكر (فارماسفيرز 710-850&mu;)، هايبروميلوز (ميثوسيل E5 LV)، كروسبوفيدون (كوليدون CL M)، التلك (تلك لوزيناك فارما) ، السكروز (P.G السكر # 40 # 80)، كاربوكسي ميثيل إيثيل السليلوز (CMEC) ، بوفيدون (بلاسيدون K29 / 32) ، الكحول الآيزوبروبيلي .</p><p dir="RTL">الصواغات الأخرى للكسوة الخارجية: أوبادري الأبيض &quot; YS-1-7003 &quot;، التلك (التلك -لوزيناك فارما) ، والمياه النقية .</p><p dir="RTL">الكبسولة الجيلاتينة الفارغة مقاس &quot;3&quot; ، غطاء الكبسولة لونه أزرق قاتم و لون جسم الكبسولة &nbsp;أبيض قاتم مطبوع على الغطاء &quot; H&quot; و &#39;191&#39; على الجسم ، الطباعة لونها أصفر ذهبي .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل ديوروتين ومحتويات العلبة؟</strong></p><p dir="RTL"><strong>ديوروتين كبسولات 30 ملغم</strong></p><p dir="RTL">كبسولات جيلاتينة الفارغة مقاس &quot;3&quot; ، غطاء الكبسولة لونه أزرق قاتم و لون جسم الكبسولة &nbsp;أبيض قاتم مطبوع على الغطاء &quot; H&quot; و &#39;191&#39; على الجسم ، الطباعة لونها أصفر ذهبي . تحتوي على حبيبات ذات اللون الأبيض إلى الأبيض القاتم .</p><p dir="RTL"><strong>ديوروتين كبسولات 60 ملغم</strong></p><p dir="RTL">كبسولات جيلاتينة الفارغة مقاس &quot;3&quot; ، غطاء الكبسولة لونه أزرق قاتم و لون جسم الكبسولة أخضر قاتم مطبوع على الغطاء &quot; H&quot; و &#39;192&#39; على الجسم ، الطباعة لونها أصفر ذهبي . تحتوي على حبيبات ذات اللون الأبيض إلى الأبيض القاتم .</p><p dir="RTL"><strong>توافر ديوروتين كبسولات بالسوق</strong></p><p dir="RTL">يتوافر ديوروتين كبسولات على شكل علبة</p><p dir="RTL">ديوروتين كبسولات 30 ملغم &ndash; علبة تحتوي على ثلاثين كبسولة عبارة عن ثلاثة شرائط تحتوي على 10 كبسولات</p><p dir="RTL">ديوروتين كبسولات 60 ملغم &ndash; علبة تحتوي على ثلاثين كبسولة عبارة عن ثلاثة شرائط تحتوي على 10 كبسولات</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والمصنع </strong></p><p dir="RTL"><strong>المصنع:&nbsp; </strong></p><p dir="RTL"><strong>شركة هیترو&nbsp;&nbsp; </strong></p><p dir="RTL"><strong>حیدر اباد &ndash; تیلانقا &ndash; الهند&nbsp; </strong></p><p dir="RTL">هاتف : ٠٠٩١٨٤٥٨٢٧٥٣١٤&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صاحب حق التسویق: </strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong><br />شارع الجامعة &ndash; الملز - الریاض المملكة العربیة السعودیة .&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">هاتف : ٠٠٩٦٦١١٤٧٧٢٢١٥&nbsp; &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مایو/  ٢٠١٨
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Durotine (Duloxetine Delayed Release Capsules USP 30mg and 60mg) 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Durotine 30mg 
Each delayed release capsule contains Duloxetine Hydrochloride equivalent to Duloxetine 30 mg
 Durotine 60mg 
Each delayed release capsule contains Duloxetine Hydrochloride equivalent to Duloxetine 60 mg For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Durotine 30mg 
Opaque blue cap /Opaque white body size '3' hard gelatin capsule imprinted with 'H' on cap and '191' on body, filled with white to off white colored pellets. 
Durotine 60mg 
Opaque blue cap /Opaque green body size '1' hard gelatin capsule imprinted with 'H' on cap and '192' on body, filled with white to off white colored pellets. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of major depressive disorder.</p><p>Treatment of diabetic peripheral neuropathic pain.</p><p>Treatment of generalised anxiety disorder.</p><p>Durotine is indicated in adults.</p><p>For further information see section 5.1</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Major Depressive Disorder</p><p>The starting and recommended maintenance dose is 60 mg once daily with or without food. Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day have been evaluated from a safety perspective in clinical trials. However, there is no clinical evidence suggesting that patients not responding to the initial recommended dose may benefit from dose up-titrations.</p><p>Therapeutic response is usually seen after 2-4 weeks of treatment.</p><p>After consolidation of the antidepressive response, it is recommended to continue treatment for several months, in order to avoid relapse. In patients responding to duloxetine, and with a history of repeated episodes of major depression, further long-term treatment at a dose of 60 to 120 mg/day could be considered.</p><p>Generalised Anxiety Disorder</p><p>The recommended starting dose in patients with generalised anxiety disorder is 30 mg once daily with or without food. In patients with insufficient response the dose should be increased to 60 mg, which is the usual maintenance dose in most patients.</p><p>In patients with co-morbid major depressive disorder, the starting and maintenance dose is 60 mg once daily (please see also dosing recommendation above).</p><p>Doses up to 120 mg per day have been shown to be efficacious and have been evaluated from a safety perspective in clinical trials. In patients with insufficient response to 60 mg, escalation up to 90 mg or 120 mg may therefore be considered. Dose escalation should be based upon clinical response and tolerability.</p><p>After consolidation of the response, it is recommended to continue treatment for several months, in order to avoid relapse.</p><p>Diabetic Peripheral Neuropathic Pain</p><p>The starting and recommended maintenance dose is 60 mg daily with or without food. Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day administered in evenly</p><p>&nbsp;</p><p>divided doses, have been evaluated from a safety perspective in clinical trials. The plasma concentration of duloxetine displays large inter-individual variability (see section 5.2). Hence, some patients that respond insufficiently to 60 mg may benefit from a higher dose.</p><p>Response to treatment should be evaluated after 2 months. In patients with inadequate initial response, additional response after this time is unlikely.</p><p>The therapeutic benefit should be reassessed regularly (at least every three months) (see section 5.1).</p><p><em>Special populations</em></p><p>Elderly</p><p>No dosage adjustment is recommended for elderly patients solely on the basis of age. However, as with any medicine, caution should be exercised when treating the elderly, especially with Durotine 120 mg per day for major depressive disorder or generalised anxiety disorder, for which data are limited (see sections 4.4 and 5.2).</p><p>Hepatic Impairment</p><p>Durotine must not be used in patients with liver disease resulting in hepatic impairment (see sections 4.3 and 5.2).</p><p>Renal Impairment</p><p>No dosage adjustment is necessary for patients with mild or moderate renal dysfunction (creatinine clearance 30 to 80 ml/min). Durotine must not be used in patients with severe renal impairment (creatinine clearance &lt;30 ml/min; see section 4.3).</p><p>Paediatric population</p><p>Duloxetine should not be used in children and adolescents under the age of 18 years for the treatment of major depressive disorder because of safety and efficacy concerns (see sections 4.4, 4.8 and 5.1).</p><p>The safety and efficacy of duloxetine for the treatment of generalised anxiety disorder in paediatric patients aged 7-17 years have not been established. Current available data are described in sections 4.8, 5.1 and 5.2.</p><p>The safety and efficacy of duloxetine for the treatment of diabetic peripheral neuropathic pain has not been studied. No data are available.</p><p>Discontinuation of Treatment</p><p>Abrupt discontinuation should be avoided. When stopping treatment with Durotine the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p><em><u>Method of administration</u></em><br />For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Concomitant use of Durotine with non-selective, irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated (see section 4.5). 
Liver disease resulting in hepatic impairment (see section 5.2). 
Durotine should not be used in combination with fluvoxamine, ciprofloxacin or enoxacin (i.e. potent CYP1A2 inhibitors) since the combination results in elevated plasma concentrations of duloxetine (see section 4.5). 
Severe renal impairment (creatinine clearance <30 ml/min) (see section 4.4).  
The initiation of treatment with Durotine is contraindicated in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis (see sections 4.4 and 4.8). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mania and Seizures</p><p>Durotine should be used with caution in patients with a history of mania or a diagnosis of bipolar disorder, and/or seizures.</p><p>Mydriasis</p><p>Mydriasis has been reported in association with duloxetine, therefore, caution should be used when prescribing Durotine to patients with increased intraocular pressure or those at risk of acute narrow-angle glaucoma.</p><p>Blood Pressure and Heart Rate</p><p>Duloxetine has been associated with an increase in blood pressure and clinically significant hypertension in some patients. This may be due to the noradrenergic effect of duloxetine. Cases of hypertensive crisis have been reported with duloxetine, especially in patients with pre-existing hypertension. Therefore, in patients with known hypertension and/or other cardiac disease, blood pressure monitoring is recommended, especially during the first month of treatment. Duloxetine should be used with caution in patients whose conditions could be compromised by an increased heart rate or by an increase in blood pressure. Caution should also be exercised when duloxetine is used with medicinal products that may impair its metabolism (see section 4.5). For patients who experience a sustained increase in blood pressure while receiving duloxetine either dose reduction or gradual discontinuation should be considered (see section 4.8). In patients with uncontrolled hypertension duloxetine should not be initiated (see section 4.3).</p><p>Renal Impairment</p><p>Increased plasma concentrations of duloxetine occur in patients with severe renal impairment on haemodialysis (creatinine clearance &lt;30 ml/min). For patients with severe renal impairment, see section 4.3. See section 4.2 for information on patients with mild or moderate renal dysfunction.</p><p>Serotonin syndrome</p><p>As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may occur with duloxetine treatment, particularly with concomitant use of other serotonergic agents (including SSRIs, SNRIs, tricyclic antidepressants or triptans), with agents that impair metabolism of serotonin such as MAOIs, or with antipsychotics or other dopamine antagonists that may affect the serotonergic neurotransmitter systems (see sections 4.3 and 4.5).</p><p>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea).</p><p>If concomitant treatment with duloxetine and other serotonergic agents that may affect the serotonergic and/or dopaminergic neurotransmitter systems is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p><p>St John&#39;s Wort</p><p>Adverse reactions may be more common during concomitant use of Durotine and herbal preparations containing St John&#39;s Wort (<em>Hypericum perforatum</em>).</p><p>Suicide</p><p><em>Major Depressive Disorder and Generalised Anxiety Disorder:</em> Depression is associated with an increased risk of suicidal thoughts, self-harm, and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>Other psychiatric conditions for which Durotine is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal thoughts prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or suicidal behaviour, and should receive careful monitoring during treatment. A metaanalysis of placebo-controlled clinical trials of antidepressant medicinal products in psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>Cases of suicidal thoughts and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (see section 4.8).</p><p>Close supervision of patients, and in particular those at high risk, should accompany medicinal product therapy, especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts, and unusual changes in behaviour, and to seek medical advice immediately if these symptoms present.</p><p><em>Diabetic Peripheral Neuropathic Pain: </em>As with other medicinal products with similar pharmacological action (antidepressants), isolated cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation. Concerning risk factors for suicidality in depression, see above. Physicians should encourage patients to report any distressing thoughts or feelings at any time.</p><p>Use in Children and Adolescents Under 18 Years of Age</p><p>Durotine should not be used in the treatment of children and adolescents under the age of 18 years. Suicide-related behaviours (suicide attempts and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour, and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms (see section 5.1). In addition, long-term safety data in children and adolescents concerning growth, maturation, and cognitive and behavioural development are lacking (see section 4.8).</p><p>Haemorrhage</p><p>There have been reports of bleeding abnormalities, such as ecchymoses, purpura, and gastrointestinal haemorrhage, with selective serotonin reuptake inhibitors (SSRIs) and serotonin/noradrenaline reuptake inhibitors (SNRIs), including duloxetine. Duloxetine may increase the risk of postpartum haemorrhage (see section 4.6). Caution is advised in patients taking anticoagulants and/or medicinal products known to affect platelet function (e.g., NSAIDs or acetylsalicylic acid (ASA)), and in patients with known bleeding tendencies.</p><p>Hyponatraemia</p><p>Hyponatraemia has been reported when administering Durotine, including cases with serum sodium lower than 110 mmol/l. Hyponatraemia may be due to a syndrome of inappropriate antidiuretic hormone secretion (SIADH). The majority of cases of hyponatraemia were reported in the elderly, especially when coupled with a recent history of, or condition pre-disposing to, altered fluid balance. Caution is required in patients at increased risk for hyponatraemia, such as elderly, cirrhotic, or dehydrated patients, or patients treated with diuretics.</p><p>Discontinuation of Treatment</p><p>Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials, adverse events seen on abrupt treatment discontinuation occurred in approximately 45% of patients treated with Durotine and 23% of patients taking placebo.</p><p>The risk of withdrawal symptoms seen with SSRIs and SNRIs may be dependent on several factors, including the duration and dose of therapy and the rate of dose reduction. The most commonly reported reactions are listed in section 4.8. Generally, these symptoms are mild to moderate, however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. Generally, these symptoms are selflimiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that duloxetine should be gradually tapered when discontinuing treatment over a period of no less than 2 weeks, according to the patient&#39;s needs (see section 4.2).</p><p>Elderly</p><p>Data on the use of Durotine 120 mg in elderly patients with major depressive disorder and generalised anxiety disorder are limited. Therefore, caution should be exercised when treating the elderly with the maximum dosage (see sections 4.2 and 5.2).</p><p>Akathisia/Psychomotor Restlessness</p><p>The use of duloxetine has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move, often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p>Medicinal Products Containing Duloxetine</p><p>Duloxetine is used under different trademarks in several indications (treatment of diabetic neuropathic pain, major depressive disorder, generalised anxiety disorder and stress urinary incontinence). The use of more than one of these products concomitantly should be avoided.</p><p>Hepatitis/Increased Liver Enzymes</p><p>Cases of liver injury, including severe elevations of liver enzymes (&gt;10 times upper limit of normal), hepatitis, and jaundice have been reported with duloxetine (see section 4.8). Most of them occurred during the first months of treatment. The pattern of liver damage was predominantly hepatocellular. Duloxetine should be used with caution in patients treated with other medicinal products associated with hepatic injury.</p><p>Sexual dysfunction</p><p>Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRIs.</p><p>Sucrose</p><p>Durotine hard gastro-resistant capsules contain sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p><p>Sodium</p><p>This medicine contains sodium that has to be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Monoamine Oxidase Inhibitors (MAOIs):</em></p><p>Due to the risk of serotonin syndrome, duloxetine should not be used in combination with nonselective, irreversible monoamine oxidase inhibitors (MAOIs) or within at least 14 days of discontinuing treatment with an MAOI. Based on the half-life of duloxetine, at least 5 days should be allowed after stopping Durotine before starting an MAOI (see section 4.3).</p><p>The concomitant use of Durotine with selective, reversible MAOIs, like moclobemide, is not recommended (see section 4.4). The antibiotic linezolid is a reversible non-selective MAOI and should not be given to patients treated with Durotine (see section 4.4).</p><p><em>Inhibitors of CYP1A2: </em>Because CYP1A2 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP1A2 is likely to result in higher concentrations of duloxetine. Fluvoxamine (100 mg once daily), a potent inhibitor of CYP1A2, decreased the apparent plasma clearance of duloxetine by about 77% and increased AUC<sub>o-t</sub> 6-fold. Therefore, Durotine should not be administered in combination with potent inhibitors of CYP1A2 like fluvoxamine (see section 4.3).</p><p><em>CNS Medicinal Products: </em>The risk of using duloxetine in combination with other CNS-active medicinal products has not been systematically evaluated, except in the cases described in this section. Consequently, caution is advised when Durotine is taken in combination with other centrally-acting medicinal products or substances, including alcohol and sedative medicinal products (e.g., benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).</p><p><em>Serotonergic agents: </em>In rare cases, serotonin syndrome has been reported in patients using SSRIs/SNRIs concomitantly with serotonergic agents. Caution is advisable if Durotine is used concomitantly with serotonergic agents like SSRIs, SNRIs, tricyclic antidepressants like clomipramine or amitriptyline, MAOIs like moclobemide or linezolid, St John&#39;s Wort (<em>Hypericum perforatum</em>) or triptans, tramadol, pethidine, and tryptophan (see section 4.4).</p><p>Effect of Duloxetine on Other Medicinal Products</p><p><em>Medicinal products metabolised by CYP1A2:</em> The pharmacokinetics of theophylline, a CYP1A2 substrate, were not significantly affected by co-administration with duloxetine (60 mg twice daily).</p><p><em>Medicinal products metabolised by CYP2D6:</em> Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold. The coadministration of duloxetine (40 mg twice daily) increases steady-state AUC of tolterodine (2 mg twice daily) by 71%, but does not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is recommended. Caution is advised if Durotine is co-administered with medicinal products that are predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), particularly if they have a narrow therapeutic index (such as flecainide, propafenone, and metoprolol).</p><p><em>Oral contraceptives and other steroidal agents:</em> Results of <em>in vitro </em>studies demonstrate that duloxetine does not induce the catalytic activity of CYP3A. Specific <em><sub>in vivo</sub></em> drug interaction studies have not been performed.</p><p><em>Anticoagulants and antiplatelet agents:</em> Caution should be exercised when duloxetine is combined with oral anticoagulants or antiplatelet agents due to a potential increased risk of bleeding attributable to a pharmacodynamic interaction. Furthermore, increases in INR values have been reported when duloxetine was co-administered to patients treated with warfarin. However, concomitant administration of duloxetine with warfarin under steady-state conditions, in healthy volunteers, as part of a clinical pharmacology study, did not result in a clinically significant change in INR from baseline or in the pharmacokinetics of R- or S-warfarin.</p><p>Effects of Other Medicinal Products on Duloxetine</p><p><em>Antacids and H<sub>2</sub> antagonists:</em> Co-administration of duloxetine with aluminium- and magnesiumcontaining antacids, or duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose.</p><p><em>Inducers of CYP1A2:</em> Population pharmacokinetic analyses have shown that smokers have almost 50% lower plasma concentrations of duloxetine compared with non-smokers.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fertility</p><p>In animal studies, duloxetine had no effect on male fertility, and effects in females were only evident at doses that caused maternal toxicity.</p><p>Pregnancy</p><p>Studies in animals have shown reproductive toxicity at systemic exposure levels (AUC) of duloxetine lower than the maximum clinical exposure (see section 5.3).</p><p>Two large observational studies do not suggest an overall increased risk of major congenital malformation (one from the US including 2,500 exposed to duloxetine during the first trimester and one from the EU including 1,500 exposed to duloxetine during the first trimester). The analysis on specific malformations such as cardiac malformations shows inconclusive results.</p><p>In the EU study, maternal exposure to duloxetine during late pregnancy (at any time from 20 weeks gestational age to delivery) was associated with an increased risk for preterm birth (less than 2-fold, corresponding to approximately 6 additional premature births per 100 women treated with duloxetine late in pregnancy). The majority occurred between 35 and 36 weeks of gestation. This association was not seen in the US study.</p><p>The US observational data have provided evidence of an increased risk (less than 2-fold) of postpartum haemorrhage following duloxetine exposure within the month prior to birth.</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated the association of PPHN to SNRI treatment, this potential risk cannot be ruled out with duloxetine, taking into account the related mechanism of action (inhibition of the re-uptake of serotonin).</p><p>As with other serotonergic medicinal products, discontinuation symptoms may occur in the neonate after maternal duloxetine use near term. Discontinuation symptoms seen with duloxetine may include hypotonia, tremor, jitteriness, feeding difficulty, respiratory distress and seizures. The majority of cases have occurred either at birth or within a few days of birth.</p><p>Durotine should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus. Women should be advised to notify their physician if they become pregnant, or intend to become pregnant, during therapy.</p><p>Breast-Feeding</p><p>Duloxetine is very weakly excreted into human milk, based on a study of 6 lactating patients who did not breast-feed their children. The estimated daily infant dose on a mg/kg basis is approximately 0.14% of the maternal dose (see section 5.2). As the safety of duloxetine in infants is not known, the use of Durotine while breast-feeding is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Durotine may be associated with sedation and dizziness. Patients should be instructed that if they experience sedation or dizziness they should avoid potentially hazardous tasks such as driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile</p><p>The most commonly reported adverse reactions in patients treated with Durotine were nausea, headache, dry mouth, somnolence and dizziness. However, the majority of common adverse reactions were mild to moderate; they usually started early in therapy, and most tended to subside even as therapy was continued.</p><p>b. Tabulated summary of adverse reactions</p><p><em>Table 1</em> gives the adverse reactions observed from spontaneous reporting and in placebocontrolled clinical trials.</p><p>Table 1: Adverse reactions</p><p><em>Frequency estimate:</em> Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Very common</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Very Rare</strong></p></td></tr><tr><td colspan="2"><p><em>Infections and infestations</em>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Laryngitis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p><em>Immune system disorders</em>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Anaphylactic</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>reaction</p><p>Hypersensitivity disorder</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Endocrine disorders</em>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Hypothyroidism</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Metabolism and nutrition disorders</em>&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Decreased appetite</p></td><td><p>Hyperglycaemia</p><p>(reported especially in diabetic patients)</p></td><td><p>Dehydration</p><p>Hyponatraemia SIADH<sup>6</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Psychiatric disorders</em>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Insomnia Agitation</p><p>Libido decreased</p><p>Anxiety</p><p>Orgasm abnormal</p><p>Abnormal dreams</p></td><td><p>Suicidal ideation <sup>5,7</sup></p><p>Sleep disorder</p><p>Bruxism</p><p>Disorientation Apathy</p></td><td><p>Suicidal behaviour<sup>5,7</sup></p><p>Mania</p><p>Hallucinations Aggression and anger<sup>4</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Nervous system disorders</em>&nbsp;</p></td></tr><tr><td><p>Headache Somnolence</p></td><td><p>Dizziness</p><p>Lethargy</p><p>Tremor</p><p>Paraesthesia</p></td><td><p>Myoclonus</p><p>Akathisia<sup>7</sup></p><p>Nervousness Disturbance in attention Dysgeusia</p><p>Dyskinesia Restless legs syndrome</p><p>Poor quality sleep</p></td><td><p>Serotonin syndrome<sup>6</sup></p><p>Convulsion<sup>1</sup> Psychomotor restlessness<sup>6</sup> Extra-pyramidal symptoms<sup>6</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Eye disorders</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Blurred vision</p></td><td><p>Mydriasis</p><p>Visual impairment</p></td><td><p>Glaucoma</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Ear and labyrinth disorders</em>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Tinnitus<sup>1</sup></p></td><td><p>Vertigo Ear pain</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Cardiac disorders</em></p></td></tr></tbody></table><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Palpitations</p></td><td><p>Tachycardia Supraventricular arrhythmia, mainly atrial fibrillation</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Vascular disorders</em>&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Blood pressure increase<sup>3</sup> Flushing</p></td><td><p>Syncope<sup>2</sup></p><p>Hypertension<sup>3, 7</sup> Orthostatic hypotension<sup>2</sup> Peripheral coldness</p></td><td><p>Hypertensive</p><p>crisis<sup>3,6</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Respiratory, thoracic and mediastinal disorders</em>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td colspan="5"><p><!--[if gte vml 1]><v:group id="Group_x0020_26449" o:spid="_x0000_s1035"
   style='position:absolute;left:0;text-align:left;margin-left:77.3pt;
   margin-top:-.1pt;width:.7pt;height:66.5pt;z-index:251659264;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,8442" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_29354" o:spid="_x0000_s1036" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_29355" o:spid="_x0000_s1037" style='position:absolute;
    top:197;width:91;height:8245;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,824497" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,824497l,824497,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:path arrowok="t" textboxrect="0,0,9144,824497"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="89" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_26450" o:spid="_x0000_s1032" style='position:absolute;
   left:0;text-align:left;margin-left:180.7pt;margin-top:-.1pt;width:.7pt;
   height:66.5pt;z-index:251660288;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="91,8442" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_29358" o:spid="_x0000_s1033" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_29359" o:spid="_x0000_s1034" style='position:absolute;
    top:197;width:91;height:8245;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,824497" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,824497l,824497,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:path arrowok="t" textboxrect="0,0,9144,824497"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="89" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_26451" o:spid="_x0000_s1029" style='position:absolute;
   left:0;text-align:left;margin-left:294.6pt;margin-top:-.1pt;width:.7pt;
   height:66.5pt;z-index:251661312;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="91,8442" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAvIWaUwgDAADdCgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsVt1umzAUvp+0d0C+bwmEJBCVVmu3
9WZaq6Z7ANeYgGZsZJw03dPv+A9IonbdJm3StFbCxj7nO9/5DWcXu4YFWyq7WvAcRacTFFBORFHz
dY6+3H88SVHQKcwLzASnOXqiHbo4f/vmDC/XErdVTQJA4N0S56hSql2GYUcq2uDuVLSUw10pZIMV
vMp1WEj8CMgNC+PJZB42uObofIB6jxUONrL+BSgmyFdaXGG+xR1AMrIcnziOjPw+Ml7y7bVsV+2t
1MzJ5+2tDOoiRxA5jhsIEQrdhROD1/BAaz0A7ErZaHlRlsEuR8ksXaSLGQqeYD9NFnE0sXh0pwIC
AmmagSUC12kyzaKZs1bd/ECfVB9eQACClghsRuTMVrN7xud4nswi7/e1FJs2sEd/MwQQHoiOC9vg
dhYliQ9cEmdzHbhn3O5a6/NxkuNsOo+9w6sKtzSwR95hreIT7tU7VysHqd7j6dM7sIyyNIr3SEK1
bTp1TYUpGLz91Cljdl34Ha78juy430pKVMBMgSrzlOb50MeoxUrraZ/1NnjMkaVRwUQwLPRVI7b0
XhghpSt1RB/CONwyPpayQD4fIOiv/doasF5s7LUX8asVtXZfK2fKoDcLG+2hSXzvNRyO48q4DgBY
IbjNUcmwMiMKipsXNrOMGwCfVrVbmXpRu0tRPOkAPcAKUwHGqrqBR8kEIBJWtyiohPx2cGZyyDq1
Uk+MmhcDR3lxiyW+AyCG9TTG8mT1zhUESADtweKmo6v2DhJtGXpKnYbUjBi/oyWMKZM3fdDJ9cMV
A45YV4b5M25i1lbYnTpbTtRYNDhav6wZ6yEjo7oHubjU/w7BCWs9WpbAstecWE3i2NjKBF8h/L4+
wc9eyVgWfNDn8KPkaVpfQdy278tNPD1u4qkGMhP9p5s4yhZZZtWPGzmNkyRbOJZ+Bowr7s90sqOh
XRyaddxSvlWG2/3G63vUC/prvx608p7fXsavY8OvFtw3DJn+38zHnfcPNjNk2n2JhAcfdmYouQ9R
/fU4fj//DgAA//8DAFBLAwQUAAYACAAAACEAkn2H4B0HAABJIAAAGgAAAGNsaXBib2FyZC90aGVt
ZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2xZL1iI3JgyXLcxC9ESoocKYnaZcxdLkjKjm5Fcuql
QIG06KEBeuuhKBqgARr00h9jwEGb/ogOuS9SouIHXCAobAHG7uw3w+HM7Mzs8M7dZxH1jjEXhMVt
v3qr4ns4HrExiYO2/2iw/dlt3xMSxWNEWYzb/gwL/+7Gp5/cQesjSpIhQ3w8CHGEPRAUi3XU9kMp
k/WVFTECMhK3WIJjeDZhPEISbnmwMuboBBaI6MpqpdJciRCJ/Q2QKJWgHoV/sRSKMKK8r8RgL0YR
rH4wmZAR1tjxUVUhxEx0KfeOEW37IHPMTgb4mfQ9ioSEB22/ov/8lY07K2g9Y6JyCa/Bt63/Mr6M
YXy0qtfkwbBYtF5v1JubhXwNoHIR12v1mr1mIU8D0GgEO011sWW2Vrv1DGuA0kuH7K3WVq1q4Q35
tQWdNxvqZ+E1KJVfX8Bvb3fBihZeg1J8YwHf6Kx1tmz5GpTimwv4VmVzq96y5GtQSEl8tICuNJq1
br7bAjJhdMcJX2vUt1urmfASBdFQRJdaYsJiuSzWIvSU8W0AKCBFksSenCV4gkYQk11EyZATb5cE
IQRegmImgFxZrWxXavBf/er6SnsUrWNkcCu9QBOxQFL6eGLESSLb/n2Q6huQs7dvT5+/OX3+++mL
F6fPf83W1qIsvh0UBybf+5+++efVl97fv/34/uW36dLzeGHi3/3y1bs//vyQeNhxaYqz716/e/P6
7Puv//r5pUP6JkdDEz4gERbePj7xHrIINujQHw/55TgGISImx2YcCBQjtYpDfk+GFnp/hihy4DrY
tuNjDqnGBbw3fWop3A/5VBKHxAdhZAH3GKMdxp1WeKDWMsw8mMaBe3E+NXEPETp2rd1FseXl3jSB
HEtcIrshttQ8pCiWKMAxlp56xo4wduzuCSGWXffIiDPBJtJ7QrwOIk6TDMjQiqaSaYdE4JeZS0Hw
t2Wbvcdeh1HXrrfwsY2EdwNRh/IDTC0z3kNTiSKXyAGKqGnwXSRDl5L9GR+ZuJ6Q4OkAU+b1xlgI
F88Bh/0aTn8Aacbt9j06i2wkl+TIJXMXMWYit9hRN0RR4sL2SRya2M/FEYQo8g6ZdMH3mP2GqHvw
A4qXuvsxwZa7z88GjyDDmiqVAaKeTLnDl/cws+K3P6MThF2pZpNHVord5MQZHZ1pYIX2LsYUnaAx
xt6jzx0adFhi2bxU+n4IWWUHuwLrPrJjVd3HWGBPNzeLeXKXCCtk+zhgS/TZm80lnhmKI8SXSd4H
r5s270Gpi1wBcEBHRyZwn0C/B/HiNMqBABlGcC+Vehgiq4Cpe+GO1xm3/HeRdwzey6eWGhd4L4EH
X5oHErvJ80HbDBC1FigDZoCgy3ClW2Cx3F+yqOKq2aZOvon90pZugO7IanoiEp/bAc31Po3/rveB
DuPsh1eOl+16+h23YCtZXbLTWZZMdub6m2W4+a6my/iYfPxNzRaaxocY6shixrrpaW56Gv9/39Ms
e59vOpll/cZNJ+NDh3HTyWTDlevpZMrmBfoaNfBIBz167BMtnfpMCKV9OaN4V+jBj4DvmfE2EBWf
nm7iYgqYhHCpyhwsYOECjjSPx5n8gsiwH6IEpkNVXwkJRCY6EF7CBAyNNNkpW+HpNNpj43TYWa2q
wWZaWQWSJb3SKOgwqJIputkqB3iFeK1toAetuQKK9zJKGIvZStQcSrRyojKSHuuC0RxK6J1dixZr
Di1uK/G5qxa0ANUKr8AHtwef6W2/UQcWYIJ5HDTnY+Wn1NW5d7Uzr9PTy4xpRQA02HkElJ5eU7ou
3Z7aXRpqF/C0pYQRbrYS2jK6wRMhfAZn0amoF1Hjsr5eK11qqadModeD0CrVaN3+kBZX9TXwzecG
GpuZgsbeSdtv1hoQMiOUtP0JDI3hMkogdoT65kI0gOOWkeTpC3+VzJJwIbeQCFOD66STZoOISMw9
SqK2r7ZfuIHGOodo3aqrkBA+WuXWIK18bMqB020n48kEj6TpdoOiLJ3eQoZPc4XzqWa/Olhxsim4
ux+OT7whnfKHCEKs0aoqA46JgLODamrNMYHDsCKRlfE3V5iytGueRukYSumIJiHKKoqZzFO4TuWF
OvqusIFxl+0ZDGqYJCuEw0AVWNOoVjUtqkaqw9Kqez6TspyRNMuaaWUVVTXdWcxaIS8Dc7a8WpE3
tMpNDDnNrPBp6p5PuWt5rpvrE4oqAQYv7OeouhcoCIZq5WKWakrjxTSscnZGtWtHvsFzVLtIkTCy
fjMXO2e3okY4lwPilSo/8M1HLZAmeV+pLe062N5DiTcMqm0fDpdhOPgMruB42gfaqqKtKhpcwZkz
lIv0oLjtZxc5BZ6nlAJTyym1HFPPKfWc0sgpjZzSzClN39MnqnCKrw5TfS8/MIUalh2wZr2Fffq/
8S8AAAD//wMAUEsDBBQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdz
L19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzhI/NCsIwEITvgu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR
7Nsb6EVB8LIws+w3s037sjN5YkyTdxxqWgFBp7yenOFw6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKU
xikkUigucRhzDifGkhrRykR9QFc2g49W5iKjYUGquzTI9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/th
mBSevXpYdPlHBMulFxagjAYzB0pXZ501LV2BiYZ9/SbeAAAA//8DAFBLAQItABQABgAIAAAAIQC7
5UiUBQEAAB4CAAATAAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAG
AAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAAAAAAAAAANgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAG
AAgAAAAhALyFmlMIAwAA3QoAAB8AAAAAAAAAAAAAAAAAIAIAAGNsaXBib2FyZC9kcmF3aW5ncy9k
cmF3aW5nMS54bWxQSwECLQAUAAYACAAAACEAkn2H4B0HAABJIAAAGgAAAAAAAAAAAAAAAABlBQAA
Y2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWxQSwECLQAUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAA
AAAAAAAAAAAAAAC6DAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxz
UEsFBgAAAAAFAAUAZwEAAL0NAAAAAA==
">
   <v:shape id="Shape_x0020_29362" o:spid="_x0000_s1030" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_29363" o:spid="_x0000_s1031" style='position:absolute;
    top:197;width:91;height:8245;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,824497" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,824497l,824497,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:path arrowok="t" textboxrect="0,0,9144,824497"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="89" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_26452" o:spid="_x0000_s1026" style='position:absolute;
   left:0;text-align:left;margin-left:398.9pt;margin-top:-.1pt;width:.7pt;
   height:66.5pt;z-index:251662336;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="91,8442" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_29366" o:spid="_x0000_s1027" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_29367" o:spid="_x0000_s1028" style='position:absolute;
    top:197;width:91;height:8245;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,824497" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,824497l,824497,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:path arrowok="t" textboxrect="0,0,9144,824497"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="89" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />Yawning Throat tightness Interstitial lung</p><p>Epistaxis disease<sup>10</sup></p><p>Eosinophilic pneumonia<sup>6</sup></p></td></tr><tr><td colspan="5"><p><em>Gastrointestinal disorders</em>&nbsp;</p></td></tr><tr><td><p>Nausea</p><p>Dry mouth</p></td><td><p>Constipation</p><p>Diarrhoea</p><p>Abdominal pain</p><p>Vomiting</p><p>Dyspepsia Flatulence</p></td><td><p>Gastrointestinal haemorrhage<sup>7</sup></p><p>Gastroenteritis</p><p>Eructation</p><p>Gastritis</p><p>Dysphagia</p></td><td><p>Stomatitis</p><p>Haematochezia</p><p>Breath odour</p><p>Microscopic colitis<sup>9</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Hepato-biliary disorders</em>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Hepatitis<sup>3</sup></p><p>Elevated liver enzymes (ALT, AST, alkaline phosphatase) Acute liver injury</p></td><td><p>Hepatic failure<sup>6</sup> Jaundice<sup>6</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><em>Skin and subcutaneous tissue disorders</em>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Sweating increased Rash</p></td><td><p>Night sweats Urticaria</p><p>Dermatitis contact</p><p>Cold sweat Photosensitivity reactions</p><p>Increased tendency to</p></td><td><p>Stevens-Johnson</p><p>Syndrome<sup>6</sup> Angioneurotic oedema<sup>6</sup></p></td><td><p>Cutaneous vasculitis</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>bruise</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p><em>Musculoskeletal and connective tissue disorders</em>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Musculoskeletal pain</p><p>Muscle spasm</p></td><td><p>Muscle tightness Muscle twitching</p></td><td><p>Trismus</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p><em>Renal and urinary disorders</em>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dysuria</p><p>Pollakiuria</p></td><td><p>Urinary retention</p><p>Urinary hesitation</p><p>Nocturia</p><p>Polyuria</p><p>Urine flow decreased</p></td><td><p>Urine odour abnormal</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p><em>Reproductive system and breast disorders</em>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Erectile dysfunction</p><p>Ejaculation disorder</p><p>Ejaculation delayed</p></td><td><p>Gynaecological haemorrhage Menstrual disorder</p><p>Sexual dysfunction</p><p>Testicular pain</p></td><td><p>Menopausal symptoms</p><p>Galactorrhoea</p><p>Hyperprolactinaemia Postpartum haemorrhage<sup>6</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p><em>General disorders and administration site conditions</em>&nbsp;</p></td><td colspan="2"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Falls<sup>8</sup> Fatigue</p></td><td><p>Chest pain<sup>7</sup></p><p>Feeling abnormal</p><p>Feeling cold</p><p>Thirst</p><p>Chills</p><p>Malaise</p><p>Feeling hot</p><p>Gait disturbance</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p><em>Investigations</em></p><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Weight decrease</p></td><td><p>Weight increase Blood creatine phosphokinase increased Blood potassium increased</p></td><td><p>Blood cholesterol increased</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><sup>1&nbsp; </sup>Cases of convulsion and cases of tinnitus have also been reported after treatment discontinuation.</p><p><sup>2&nbsp; </sup>Cases of orthostatic hypotension and syncope have been reported especially at the initiation of treatment.</p><p><sup>3&nbsp; </sup>See section 4.4.</p><p><sup>4&nbsp; </sup>Cases of aggression and anger have been reported particularly early in treatment or after treatment discontinuation.</p><p><sup>5&nbsp; </sup>Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (see section 4.4).</p><p><sup>6&nbsp; </sup>Estimated frequency of post-marketing surveillance reported adverse reactions; not observed in placebo-controlled clinical trials.</p><p><sup>7&nbsp; </sup>Not statistically significantly different from placebo.</p><p><sup>8&nbsp; </sup>Falls were more common in the elderly (<em><sub>&ge;</sub></em>65 years old).</p><p><sup>9&nbsp; </sup>Estimated frequency based on all clinical trial data.</p><p><sup>10</sup>Estimated frequency based on placebo-controlled clinical trials.</p><p><em>c. Description of selected adverse reactions</em></p><p>Discontinuation of duloxetine (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia or electric shock-like sensations, particularly in the head), sleep disturbances (including insomnia and intense dreams), fatigue, somnolence, agitation or anxiety, nausea and/or vomiting, tremor, headache, myalgia, irritability, diarrhoea, hyperhydrosis and vertigo are the most commonly reported reactions.</p><p>Generally, for SSRIs and SNRIs, these events are mild to moderate and self-limiting; however, in some patients they may be severe and/or prolonged. It is therefore advised that when duloxetine treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see sections 4.2 and 4.4).</p><p>In the 12-week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetine-treated patients. HbA<sub>1c</sub> was stable in both duloxetine-treated and placebotreated patients. In the extension phase of these studies, which lasted up to 52 weeks, there was an increase in HbA<sub>1c</sub> in both the duloxetine and routine care groups, but the mean increase was 0.3% greater in the duloxetine-treated group. There was also a small increase in fasting blood glucose and in total cholesterol in duloxetine-treated patients, while those laboratory tests showed a slight decrease in the routine care group.</p><p>The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in placebo-treated patients. No clinically significant differences were observed for QT, PR, QRS, or QTcB measurements between duloxetine-treated and placebo-treated patients.</p><p><em>d. Paediatric population</em></p><p>A total of 509 paediatric patients aged 7 to 17 years with major depressive disorder and 241 paediatric patients aged 7 to 17 years with generalised anxiety disorder were treated with duloxetine in clinical trials. In general, the adverse reaction profile of duloxetine in children and adolescents was similar to that seen for adults.</p><p>A total of 467 paediatric patients initially randomized to duloxetine in clinical trials experienced a 0.1 kg mean decrease in weight at 10-weeks compared with a 0.9 kg mean increase in 353 placebo-treated patients. Subsequently, over the four- to six-month extension period, patients on average trended toward recovery to their expected baseline weight percentile based on population data from age- and gender-matched peers.</p><p>In studies of up to 9 months an overall mean decrease of 1% in height percentile (decrease of 2% in children (7-11 years) and increase of 0.3% in adolescents (12-17 years)) was observed in duloxetine-treated paediatric patients (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)&nbsp;</p><p><u>Reporting of suspected adverse reactions</u>&nbsp;</p><p><strong><em>&bull; </em>Saudi Arabia<em>: </em></strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o SFDA Call Center: 19999<br /><strong><em><sup>&nbsp;</sup></em></strong>o E-mail:npc.drug@sfda.gov.sa<br />o Website:https://ade.sfda.gov.sa/ &nbsp;&nbsp;&nbsp;&nbsp; <strong><em><sup>&nbsp;</sup></em></strong></p><p>&nbsp;<strong>&nbsp;</strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cases of overdoses, alone or in combination with other medicinal products, with duloxetine doses of 5400 mg were reported. Some fatalities have occurred, primarily with mixed overdoses, but also with duloxetine alone at a dose of approximately 1000 mg. Signs and symptoms of overdose (duloxetine alone or in combination with other medicinal products) included somnolence, coma, serotonin syndrome, seizures, vomiting and tachycardia.</p><p>No specific antidote is known for duloxetine, but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. A free airway should be established. Monitoring of cardiac and vital signs is recommended, along with appropriate symptomatic and supportive measures. Gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal may be useful in limiting absorption. Duloxetine has a large volume of distribution and forced diuresis, haemoperfusion, and exchange perfusion are unlikely to be beneficial.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antidepressants. ATC code: N06AX21.</p><p>Mechanism of action</p><p>Duloxetine is a combined serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor. It weakly inhibits dopamine reuptake, with no significant affinity for histaminergic, dopaminergic, cholinergic, and adrenergic receptors. Duloxetine dose-dependently increases extracellular levels of serotonin and noradrenaline in various brain areas of animals.</p><p>Pharmacodynamic effects</p><p>Duloxetine normalised pain thresholds in several preclinical models of neuropathic and inflammatory pain and attenuated pain behaviour in a model of persistent pain. The pain inhibitory action of duloxetine is believed to be a result of potentiation of descending inhibitory pain pathways within the central nervous system.</p><p>Clinical efficacy and safety</p><p><em>Major Depressive Disorder: </em>Durotine was studied in a clinical programme involving 3,158 patients (1,285 patient-years of exposure) meeting DSM-IV criteria for major depression. The efficacy of Durotine at the recommended dose of 60 mg once a day was demonstrated in three out of three randomised, double-blind, placebo-controlled, fixed-dose acute studies in adult outpatients with major depressive disorder. Overall, Durotine&#39;s efficacy has been demonstrated at daily doses between 60 and 120 mg in a total of five out of seven randomised, double-blind, placebo-controlled, fixed-dose acute studies in adult outpatients with major depressive disorder.</p><p>Durotine demonstrated statistical superiority over placebo as measured by improvement in the 17-item Hamilton Depression Rating Scale (HAM-D) total score (including both the emotional and somatic symptoms of depression). Response and remission rates were also statistically significantly higher with Durotine compared with placebo. Only a small proportion of patients included in pivotal clinical trials had severe depression (baseline HAM-D &gt;25).</p><p>In a relapse prevention study, patients responding to 12 weeks of acute treatment with open-label Durotine 60 mg once daily were randomised to either Durotine 60 mg once daily or placebo for a further 6 months. Durotine 60 mg once daily demonstrated a statistically significant superiority compared to placebo (p = 0.004) on the primary outcome measure, the prevention of depressive relapse, as measured by time to relapse. The incidence of relapse during the 6-months doubleblind, follow-up period was 17% and 29% for duloxetine and placebo, respectively.</p><p>During 52 weeks of placebo-controlled double-blind treatment, duloxetine-treated patients with recurrent MDD had a significantly longer symptom free period (p&lt;0.001) compared with patients randomised to placebo. All patients had previously responded to duloxetine during openlabel duloxetine treatment (28 to 34 weeks) at a dose of 60 to 120 mg/day. During the 52-week placebo-controlled double-blind treatment phase, 14.4% of the duloxetine-treated patients and 33.1% of the placebo-treated patients experience a return of their depressive symptoms (p&lt;0.001).</p><p>The effect of Durotine 60 mg once a day in elderly depressed patients (&ge;65 years) was specifically examined in a study that showed a statistically significant difference in the reduction of the HAM-D17 score for duloxetine-treated patients compared to placebo. Tolerability of Durotine 60 mg once daily in elderly patients was comparable to that seen in the younger adults. However, data on elderly patients exposed to the maximum dose (120 mg per day) are limited, and thus, caution is recommended when treating this population.</p><p><em>Generalised Anxiety Disorder: </em>Durotine demonstrated statistically significant superiority over placebo in five out of five studies including four randomised, double-blind, placebo-controlled acute studies and a relapse prevention study in adult patients with generalised anxiety disorder.</p><p>Durotine demonstrated statistically significant superiority over placebo as measured by improvement in the Hamilton Anxiety Scale (HAM-A) total score and by the Sheehan Disability Scale (SDS) global functional impairment score. Response and remission rates were also higher with Durotine compared to placebo. Durotine showed comparable efficacy results to venlafaxine in terms of improvements on the HAM-A total score.</p><p>In a relapse prevention study, patients responding to 6 months of acute treatment with open-label Durotine were randomised to either Durotine or placebo for a further 6 months. Durotine 60 mg to 120 mg once daily demonstrated statistically significant superiority compared to placebo (p&lt;0.001) on the prevention of relapse, as measured by time to relapse. The incidence of relapse during the 6-months double-blind, follow-up period was 14% for Durotine and 42% for placebo.</p><p>The efficacy of Durotine 30-120 mg (flexible dosing) once a day in elderly patients (&gt;65 years) with generalised anxiety disorder was evaluated in a study that demonstrated statistically significant improvement in the HAM-A total score for duloxetine-treated patients compared to placebo-treated patients. The efficacy and safety of Durotine 30-120 mg once daily in elderly patients with generalised anxiety disorder was similar to that seen in studies of younger adult patients. However, data on elderly patients exposed to the maximum dose (120 mg per day) are limited and, thus, caution is recommended when using this dose with the elderly population.</p><p><em>Diabetic Peripheral Neuropathic Pain: </em>The efficacy of Durotine as a treatment for diabetic neuropathic pain was established in 2 randomised, 12-week, double-blind, placebo-controlled, fixed-dose studies in adults (22 to 88 years) having diabetic neuropathic pain for at least 6 months. Patients meeting diagnostic criteria for major depressive disorder were excluded from these trials. The primary outcome measure was the weekly mean of 24-hour average pain, which was collected in a daily diary by patients on an 11-point Likert scale.</p><p>In both studies, Durotine 60 mg once daily and 60 mg twice daily significantly reduced pain compared with placebo. The effect in some patients was apparent in the first week of treatment. The difference in mean improvement between the two active treatment arms was not significant. At least 30% reported pain reduction was recorded in approximately 65% of duloxetine-treated patients versus 40% for placebo. The corresponding figures for at least 50% pain reduction were 50% and 26%, respectively. Clinical response rates (50% or greater improvement in pain) were analysed according to whether or not the patient experienced somnolence during treatment. For patients not experiencing somnolence, clinical response was observed in 47% of patients receiving duloxetine and 27% of patients on placebo. Clinical response rates in patients experiencing somnolence were 60% on duloxetine and 30% on placebo. Patients not demonstrating a pain reduction of 30% within 60 days of treatment were unlikely to reach this level during further treatment.</p><p>In an open-label, long-term uncontrolled study, the pain reduction in patients responding to 8 weeks of acute treatment of Durotine 60 mg once daily was maintained for a further 6 months as measured by change on the Brief Pain Inventory (BPI) 24-hour average pain item.</p><p>Paediatric population</p><p>Duloxetine has not been studied in patients under the age of 7. Two randomised, double-blind, parallel clinical trials were performed in 800 paediatric patients aged 7 to 17 years with major depressive disorder (see section 4.2). These two studies included a 10-week placebo and active (fluoxetine) controlled acute phase followed by six months period of active controlled extension treatment. Neither duloxetine (30-120 mg) nor the active control arm (fluoxetine 20-40 mg) statistically separated from placebo on change from baseline to endpoint in the Children&acute;s Depression Rating Scale-Revised (CDRS-R) total score. Discontinuation due to adverse events was higher in patients taking duloxetine compared with those treated with fluoxetine, mostly due to nausea. During the 10-week acute treatment period, suicidal behaviours were reported (duloxetine 0/333 [0%], fluoxetine 2/225 [0.9%], placebo 1/220 [0.5%]). Over the entire 36week course of the study, 6 out of 333 patients initially randomised to duloxetine and 3 out of 225 patients initially randomised to fluoxetine experienced suicidal behaviour (exposure adjusted incidence 0.039 events per patient year for duloxetine and 0.026 for fluoxetine). In addition, one patient who transitioned from placebo to duloxetine experienced a suicidal behaviour while taking duloxetine.</p><p>A randomised, double-blind, placebo-controlled study was performed in 272 patients aged 7-17 years with generalised anxiety disorder. The study included a 10 week placebo-controlled acute phase, followed by an 18 week extension treatment period. A flexible dose regimen was used in this study, to allow for slow dose escalation from 30 mg once daily to higher doses (maximum 120 mg once daily). Treatment with duloxetine showed a statistically significantly greater improvement in GAD symptoms, as measured by PARS severity score for GAD (mean difference between duloxetine and placebo of 2.7 points [95% CI 1.3-4.0]), after 10 weeks of treatment. The maintenance of the effect has not been evaluated. There was no statistically significant difference in discontinuation due to adverse events between duloxetine and placebo groups during the 10-week acute treatment phase. Two patients who transitioned from placebo to duloxetine after the acute phase experienced suicidal behaviours while taking duloxetine during the extension phase. A conclusion on the overall benefit/risk in this age group has not been established (see also sections 4.2 and 4.8).</p><p>A single study has been performed in paediatric patients with juvenile primary fibromyalgia syndrome (JPFS) in which the duloxetine-treated group did not separate from placebo group for the primary efficacy measure. Therefore, there is no evidence of efficacy in this paediatric patient population. The randomised, double-blind, placebo-controlled, parallel study of duloxetine was conducted in 184 adolescents aged 13 to 18 years (mean age 15.53 years) with JPFS. The study included a 13-week double-blind period where patients were randomised to duloxetine 30 mg/60 mg, or placebo daily. Duloxetine did not show efficacy in reducing pain as measured by primary outcome measure of Brief Pain Inventory (BPI) average pain score endpoint: least squares (LS) mean change from baseline in BPI average pain score at 13 weeks was -0.97 in the placebo group, compared with -1.62 in the duloxetine 30/60 mg group (p = 0.052). The safety results from this study were consistent with the known safety profile of duloxetine.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Durotine in all subsets of the paediatric population in the treatment of major depressive disorder, diabetic neuropathic pain and generalised anxiety disorder. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Duloxetine is administered as a single enantiomer. Duloxetine is extensively metabolised by oxidative enzymes (CYP1A2 and the polymorphic CYP2D6), followed by conjugation. The pharmacokinetics of duloxetine demonstrate large intersubject variability (generally 50-60%), partly due to gender, age, smoking status, and CYP2D6 metaboliser status.</p><p><em>Absorption:</em> Duloxetine is well absorbed after oral administration, with a C<sub>max</sub> occurring 6 hours post-dose. The absolute oral bioavailability of duloxetine ranged from 32% to 80% (mean of 50%). Food delays the time to reach the peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (approximately 11%). These changes do not have any clinical significance.</p><p><em>Distribution:</em> Duloxetine is approximately 96% bound to human plasma proteins. Duloxetine binds to both albumin and alpha<sub>1</sub>-acid glycoprotein. Protein binding is not affected by renal or hepatic impairment.</p><p><em>Biotransformation:</em> Duloxetine is extensively metabolised and the metabolites are excreted principally in urine. Both cytochromes P450-2D6 and 1A2 catalyse the formation of the two major metabolites, glucuronide conjugate of 4-hydroxy duloxetine and sulfate conjugate of 5hydroxy, 6-methoxy duloxetine. Based upon <em><sub>in vitro </sub></em>studies, the circulating metabolites of duloxetine are considered pharmacologically inactive. The pharmacokinetics of duloxetine in patients who are poor metabolisers with respect to CYP2D6 has not been specifically investigated. Limited data suggest that the plasma levels of duloxetine are higher in these patients.</p><p><em>Elimination:</em> The elimination half-life of duloxetine ranges from 8 to 17 hours (mean of 12 hours). After an intravenous dose the plasma clearance of duloxetine ranges from 22 l/hr to 46 l/hr (mean of 36 l/hr). After an oral dose the apparent plasma clearance of duloxetine ranges from 33 to 261 l/hr (mean 101 l/hr).</p><p>Special Populations</p><p><em>Gender:</em> Pharmacokinetic differences have been identified between males and females (apparent plasma clearance is approximately 50% lower in females). Based upon the overlap in the range of clearance, gender-based pharmacokinetic differences do not justify the recommendation for using a lower dose for female patients.</p><p><em>Age:</em> Pharmacokinetic differences have been identified between younger and elderly females (&ge;65 years) (AUC increases by about 25% and half-life is about 25% longer in the elderly), although the magnitude of these changes is not sufficient to justify adjustments to the dose. As a general recommendation, caution should be exercised when treating the elderly (see sections 4.2 and 4.4).</p><p><em>Renal impairment:</em> End stage renal disease (ESRD) patients receiving dialysis had 2-fold higher duloxetine C<sub>max</sub> and AUC values compared with healthy subjects. Pharmacokinetic data on duloxetine is limited in patients with mild or moderate renal impairment.</p><p><em>Hepatic impairment:</em> Moderate liver disease (Child-Pugh Class B) affected the pharmacokinetics of duloxetine. Compared with healthy subjects, the apparent plasma clearance of duloxetine was 79% lower, the apparent terminal half-life was 2.3-times longer, and the AUC was 3.7-times higher in patients with moderate liver disease. The pharmacokinetics of duloxetine and its metabolites have not been studied in patients with mild or severe hepatic insufficiency.</p><p><em>Breast-feeding mothers:</em> The disposition of duloxetine was studied in 6 lactating women who were at least 12-weeks postpartum. Duloxetine is detected in breast milk, and steady-state concentrations in breast milk are about one-fourth those in plasma. The amount of duloxetine in breast milk is approximately 7&micro;g/day while on 40 mg twice-daily dosing. Lactation did not influence duloxetine pharmacokinetics.</p><p><em>Paediatric population: </em>Pharmacokinetics of duloxetine in paediatric patients aged 7 to 17 years with major depressive disorder following oral administration of 20 to 120 mg once daily dosing regimen was characterized using population modelling analyses based on data from 3 studies. The model-predicted duloxetine steady-state plasma concentrations in paediatric patients were mostly within the concentration range observed in adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Duloxetine was not genotoxic in a standard battery of tests and was not carcinogenic in rats.</p><p>Multinucleated cells were seen in the liver in the absence of other histopathological changes in the rat carcinogenicity study. The underlying mechanism and the clinical relevance are unknown. Female mice receiving duloxetine for 2 years had an increased incidence of hepatocellular adenomas and carcinomas at the high dose only (144 mg/kg/day), but these were considered to be secondary to hepatic microsomal enzyme induction. The relevance of this mouse data to humans is unknown. Female rats receiving duloxetine (45 mg/kg/day) before and during mating and early pregnancy had a decrease in maternal food consumption and body weight, oestrous cycle disruption, decreased live birth indices and progeny survival, and progeny growth retardation at systemic exposure levels estimated to be at the most at maximum clinical exposure (AUC). In an embryotoxicity study in the rabbit, a higher incidence of cardiovascular and skeletal malformations was observed at systemic exposure levels below the maximum clinical exposure (AUC). No malformations were observed in another study testing a higher dose of a different salt of duloxetine. In prenatal/postnatal toxicity studies in the rat, duloxetine induced adverse behavioural effects in the offspring at exposures below maximum clinical exposure (AUC).</p><p>Studies in juvenile rats reveal transient effects on neurobehaviour, as well as significantly decreased body weight and food consumption; hepatic enzyme induction; and hepatocellular vacuolation at 45 mg/kg/day. The general toxicity profile of duloxetine in juvenile rats was similar to that in adult rats. The no-adverse effect level was determined to be 20 mg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Durotine</strong><strong> 30mg </strong></p><p>Each delayed release capsule contains Duloxetine Hydrochloride equivalent to Duloxetine 30 mg</p><p><strong>The other ingredients are:</strong> Sugar spheres (Pharmaspheres 710-850&mu;), Hypromellose (Methocel</p><p>E5 LV Premium), Crospovidone (Kollidon CL M), Talc (Talc Luzenac Pharma), Sucrose (P.G</p><p>Sugar #40 #80), Hypromellose Acetate Succinate (Enteract HPMC-AS 716 F), Triethyl citrate, Isopropyl alcohol, Purified Water, Empty Hard Gelatin Capsule Shells Size &#39;3&#39; (Cap - Opaque blue, imprinted with H in golden yellow &amp; Body - Opaque white, imprinted with 191 in golden yellow).</p><p>Film coating composition: Hypromellose, Titanium Dioxide, Polyethylene glycol, polysorbate 80, Talc.</p><p><strong>Durotine</strong><strong> 60mg </strong></p><p>Each delayed release capsule contains Duloxetine Hydrochloride equivalent to Duloxetine 60 mg</p><p><strong>The other ingredients are:</strong> Sugar spheres (Pharmaspheres 710-850&mu;), Hypromellose (Methocel</p><p>E5 LV Premium), Crospovidone (Kollidon CL M), Talc (Talc Luzenac Pharma), Sucrose (P.G</p><p>Sugar #40 #80), Hypromellose Acetate Succinate (Enteract HPMC-AS 716 F), Triethyl citrate, Isopropyl alcohol, Purified Water, Empty Hard Gelatin Capsule Shells Size &#39;1&#39; (Cap - Opaque blue, imprinted with H in white &amp; Body - Opaque green, imprinted with 192 in white).</p><p>Film coating composition: Hypromellose, Titanium Dioxide, Polyethylene glycol, polysorbate 80, Talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Durotine is Supplied in 10&rsquo;s Blister pack.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company, 
Aljameah Street, Malaz quarter,  
Riyadh 11441, Saudi Arabia Tel: +966 11 477 2215 Manufacture:  
Hetero Labs Limited Unit-III, India 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February-2023. 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>